Cabot Wealth Management Inc. Has $10.18 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Cabot Wealth Management Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 3.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,483 shares of the company’s stock after buying an additional 2,247 shares during the quarter. Cabot Wealth Management Inc.’s holdings in Zoetis were worth $10,180,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in Zoetis in the third quarter valued at about $31,000. First Personal Financial Services bought a new stake in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth approximately $33,000. Finally, Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $215.40.

Zoetis Stock Performance

ZTS stock opened at $160.39 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $71.82 billion, a P/E ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The business’s fifty day moving average is $166.51 and its 200-day moving average is $177.99.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.25%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.